PMID- 26066478
OWN - NLM
STAT- MEDLINE
DCOM- 20160513
LR  - 20150916
IS  - 1423-0267 (Electronic)
IS  - 0030-3755 (Linking)
VI  - 234
IP  - 2
DP  - 2015
TI  - Optical Coherence Tomographic Features and Visual Prognosis after Treatment for 
      Idiopathic Choroidal Neovascularization.
PG  - 67-72
LID - 10.1159/000430104 [doi]
AB  - BACKGROUND: The aim of this study was to determine whether pretreatment 
      spectral-domain optical coherence tomographic (SD-OCT) features are associated 
      with visual prognosis after treatment for idiopathic subfoveal choroidal 
      neovascularization (ISCNV) with intravitreal ranibizumab. METHODS: We 
      retrospectively evaluated SD-OCT images of eyes with ISCNV undergoing treatment 
      with intravitreal ranibizumab with a mean follow-up of 7 months. RESULTS: This 
      study included 22 patients (22 eyes) with a mean age of 32.7 +/- 8.1 years. In 
      univariate analysis, better final visual acuity expressed in logMAR units was 
      significantly associated with a lower amount of pretreatment ellipsoid zone 
      defects (p = 0.03; standardized correlation coefficient beta = 0.46) and a lower 
      amount of pretreatment external limiting membrane (ELM) damage (p = 0.007; beta = 
      0.56). All other SD-OCT parameters were not significantly associated with final 
      visual acuity. A higher improvement in visual acuity was marginally significantly 
      associated with larger pretreatment ellipsoid zone defects (p = 0.049; beta = 
      -0.43). CONCLUSIONS: The integrity of the outer retinal layers at baseline, in 
      particular of the ELM, is of importance in predicting the final visual outcome in 
      patients undergoing intravitreal medical therapy for ISCNV.
CI  - (c) 2015 S. Karger AG, Basel.
FAU - Cao, Xu-Sheng
AU  - Cao XS
AD  - Department of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren 
      Hospital, Capital Medical University, Beijing , China.
FAU - Peng, Xiao-Yan
AU  - Peng XY
FAU - You, Qi-Sheng
AU  - You QS
FAU - Zhang, Yong-Peng
AU  - Zhang YP
FAU - Jonas, Jost B
AU  - Jonas JB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150610
PL  - Switzerland
TA  - Ophthalmologica
JT  - Ophthalmologica. Journal international d'ophtalmologie. International journal of 
      ophthalmology. Zeitschrift fur Augenheilkunde
JID - 0054655
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Choroidal Neovascularization/*diagnosis/*drug therapy/physiopathology
MH  - Female
MH  - Fluorescein Angiography
MH  - Humans
MH  - Intravitreal Injections
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Ranibizumab/*therapeutic use
MH  - Retrospective Studies
MH  - Tomography, Optical Coherence
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
MH  - Visual Acuity/*physiology
MH  - Young Adult
EDAT- 2015/06/13 06:00
MHDA- 2016/05/14 06:00
CRDT- 2015/06/13 06:00
PHST- 2014/12/18 00:00 [received]
PHST- 2015/04/09 00:00 [accepted]
PHST- 2015/06/13 06:00 [entrez]
PHST- 2015/06/13 06:00 [pubmed]
PHST- 2016/05/14 06:00 [medline]
AID - 000430104 [pii]
AID - 10.1159/000430104 [doi]
PST - ppublish
SO  - Ophthalmologica. 2015;234(2):67-72. doi: 10.1159/000430104. Epub 2015 Jun 10.